v3.22.4
FINANCIAL INSTRUMENTS - Narrative (Details)
 1 Months Ended 2 Months Ended 12 Months Ended
Nov. 19, 2021
USD ($)
Feb. 28, 2023
USD ($)
Nov. 30, 2021
USD ($)
Apr. 30, 2019
USD ($)
Dec. 31, 2021
USD ($)
Dec. 31, 2022
USD ($)
customer
Dec. 31, 2021
USD ($)
customer
Dec. 31, 2020
USD ($)
Aug. 31, 2022
USD ($)
Financial Assets and Financial Liabilities Measured at Fair Value on a Recurring Basis:                  
Impairment of equity investment           $ (10,000,000)      
Changes in contingent consideration           (29,476,000) $ (989,000) $ 5,204,000  
Interest receivable         $ 100,000 $ 800,000 $ 100,000    
Number of major customers | customer           3 4    
Amount of allowance for doubtful accounts         0 $ 0 $ 0    
Subsequent Event                  
Financial Assets and Financial Liabilities Measured at Fair Value on a Recurring Basis:                  
Payments to acquire notes receivable   $ 4,000,000              
Accounts Receivable | Major customer one | Concentration Risk by Major Customer                  
Financial Assets and Financial Liabilities Measured at Fair Value on a Recurring Basis:                  
Concentration risk (as a percent)           34.00% 30.00%    
Accounts Receivable | Major customer two | Concentration Risk by Major Customer                  
Financial Assets and Financial Liabilities Measured at Fair Value on a Recurring Basis:                  
Concentration risk (as a percent)           19.00% 20.00%    
Accounts Receivable | Major customer three | Concentration Risk by Major Customer                  
Financial Assets and Financial Liabilities Measured at Fair Value on a Recurring Basis:                  
Concentration risk (as a percent)             17.00%    
Accounts Receivable | Major customer four | Concentration Risk by Major Customer                  
Financial Assets and Financial Liabilities Measured at Fair Value on a Recurring Basis:                  
Concentration risk (as a percent)           18.00% 11.00%    
Flexion and Myoscience Acquisition                  
Financial Assets and Financial Liabilities Measured at Fair Value on a Recurring Basis:                  
Acquisition-related contingent consideration         57,600,000 $ 28,100,000 $ 57,600,000    
Flexion Acquisition                  
Financial Assets and Financial Liabilities Measured at Fair Value on a Recurring Basis:                  
Acquisition-related contingent consideration     $ 372,300,000   46,400,000 28,100,000 46,400,000   $ 425,500,000
Contingent consideration, payment terms     60 days            
Changes in contingent consideration $ 45,200,000   $ 45,200,000   $ 1,200,000 $ 18,300,000 $ 1,200,000    
Flexion Acquisition | Level 3 | Weighted Average | Contingent Consideration | Measurement Input, Discount Rate                  
Financial Assets and Financial Liabilities Measured at Fair Value on a Recurring Basis:                  
Contingent consideration, liability, measurement input (as a percent)           0.150      
Flexion Acquisition | Level 3 | Weighted Average | Contingent Consideration | Measurement Input, Probability Of Success Of Regulatory Milestones                  
Financial Assets and Financial Liabilities Measured at Fair Value on a Recurring Basis:                  
Contingent consideration, liability, measurement input (as a percent)         0.15 0.125 0.15    
Flexion Acquisition | Level 3 | Weighted Average | Contingent Consideration | Measurement Input, Probability Of Payment Due To Likelihood Of Achievement                  
Financial Assets and Financial Liabilities Measured at Fair Value on a Recurring Basis:                  
Contingent consideration, liability, measurement input (as a percent)         1 0.50 1    
Flexion Acquisition | Level 3 | Weighted Average | Contingent Consideration | Measurement Input, Probability Of Success In Regulatory Approval                  
Financial Assets and Financial Liabilities Measured at Fair Value on a Recurring Basis:                  
Contingent consideration, liability, measurement input (as a percent)         0.15 0.25 0.15    
Myoscience Acquisition                  
Financial Assets and Financial Liabilities Measured at Fair Value on a Recurring Basis:                  
Acquisition-related contingent consideration         $ 11,200,000 $ 0 $ 11,200,000    
Contingent consideration, payment terms       60 days          
Changes in contingent consideration           11,200,000 2,200,000 $ 5,200,000  
Maximum total payments for contingent consideration possible       $ 100,000,000          
Contingent consideration           $ 43,000,000      
Myoscience Acquisition | Level 3 | Contingent Consideration | Measurement Input, Expected Milestone Payment                  
Financial Assets and Financial Liabilities Measured at Fair Value on a Recurring Basis:                  
Contingent consideration, liability, measurement input (as a percent)           0      
TELA Bio                  
Financial Assets and Financial Liabilities Measured at Fair Value on a Recurring Basis:                  
Sale of equity investment             9,100,000    
Equity securities, realized loss             $ 2,600,000